^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Small Intestinal Carcinoma |
| Drug: | BI 1823911 (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
665P - First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Published date:
10/16/2023
Excerpt:
NCT04973163 is assessing BI 1823911 monotherapy and is designed to evaluate combinations with other anticancer therapies in pts with locally advanced/metastatic solid tumours with a KRAS G12C mutation….During early dose escalation (≥100 mg), 11 pts had disease control, including 8 with stable disease and 3 with confirmed PR (600 mg, n=2, lung and unknown cancer, Day 53 and 55; 900 mg, n=1, small intestine, Day 50).
Trial ID:
